Below are the most recently updated broker updates which include ratings and price targets for Bristol-Myers Squibb Company (NYSE:BMY).

05/05/2016 – Broker: Jefferies Rating: hold New Target: 75 reiteration

04/29/2016 – Broker: Barclays Rating: equal weight New Target: 75 reiteration

04/29/2016 – Broker: UBS Rating: buy New Target: 80 reiteration

04/25/2016 – Broker: Credit Suisse Rating: overweight New Target: 70 reiteration

04/06/2016 – Broker: Societe Generale Rating: sell New Target: 48 newcoverage

02/29/2016 – Broker: Leerink Swann Rating: outperform New Target: 80 reiteration

01/29/2016 – Broker: Sanford C. Bernstein Rating: market perform New Target: 69 reiteration

01/25/2016 – Broker: BMO Capital Markets Rating: market perform New Target: 70 downgrade

01/22/2016 – Broker: Berenberg Bank Rating: buy New Target: 77 upgrade

12/18/2015 – Broker: Atlantic Equities Rating: underweight New Target: 57 newcoverage

12/14/2015 – Broker: Cowen Rating: outperform New Target: 100 reiteration

12/02/2015 – Broker: Guggenheim Rating: buy New Target: 82 upgrade

11/24/2015 – Broker: William Blair Rating: outperform reiteration

09/22/2015 – Broker: Morgan Stanley Rating: buy reiteration

08/24/2015 – Broker: Piper Jaffray Rating: neutral New Target: 61 upgrade

The average price target from the most recent broker reports is 72.62

The stock increased +0.10% (+0.07) during the last days session, reaching 71.22 and roughly 4770096 shares were bought or sold by traders.

View other investors thoughts on Bristol-Myers Squibb Company with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.